GlassScriptPhysician profile
Ute H Dreiner
NPI 1114914421
$6,902.59
in general payments reported to CMS, 2019-2025
21 companies · $1,002 in 2025
The $1,002 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,009 · 2020: $337 · 2021: $748 · 2022: $1,522 · 2023: $1,031 · 2024: $1,254 · 2025: $1,002.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,286.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,286.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,505.78 | 2019-2025 | Rinvoq, Skyrizi |
| Ucb, INC. | $1,236.33 | 2019-2025 | Cimzia, Bimzelx |
| Amgen INC. | $805.71 | 2019-2025 | Enbrel, Otezla, Amjevita |
| Pfizer INC. | $735.68 | 2019-2025 | |
| Janssen Biotech, INC. | $709.13 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $486.45 | 2021-2025 | |
| Genentech USA, INC. | $304.63 | 2019-2025 | Actemra |
| E.R. Squibb & Sons, L.L.C. | $238.95 | 2019-2025 | Orencia |
| Lilly USA, LLC | $188.44 | 2020-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $177.10 | 2022-2025 | Saphnelo |
| Glaxosmithkline, LLC. | $167.81 | 2019-2025 | Benlysta |
| Janssen Scientific Affairs, LLC | $79.91 | 2019 | |
| Genzyme Corporation | $73.60 | 2019-2023 | |
| Organon LLC | $33.54 | 2023-2024 | Renflexis, Hadlima |
| Fidia Pharma USA INC. | $31.83 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $27.11 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.66 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.75 | 2020 | |
| Celgene Corporation | $22.66 | 2019 | |
| Hospira, INC. | $15.43 | 2019 | |
| Horizon Therapeutics Plc | $12.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ute Dreiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.